A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/10 (2006.01) A61K 38/08 (2006.01) A61K 47/48 (2006.01) A61P 9/00 (2006.01) A61P 27/06 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2555792
Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.
L'angiogenèse non régulée est associée à divers état pathologiques. La croissance tumorale et la métastase dépendent du développement de nouveaux vaisseaux sanguins. Le développement de nouveaux vaisseaux dans l'oeil, ou la néovascularisation oculaire, ont été impliqués dans diverses maladies oculaires sérieuses. Par exemple, La néovascularisation choroïdienne est liée à la dégénérescence maculaire due à l'âge alors que la néovascularisation rétinienne est liée à la rétinopathie diabétique. L'invention est basée sur la découverte d'une séquence peptidique, C16Y, qui inhibe la néovascularisation oculaire et la croissance tumorale in vivo. C16Y est une version brouillée de la séquence peptidique C16 de la chaîne .gamma.1 de la laminine 1. On a constaté que, à la différence de C16, qui est un stimulateur angiogénique, C16Y inhibait l'angiogenèse. L'invention porte sur des méthodes de traitement de la néovascularisation oculaire et du cancer au moyen de versions pleine longueur et tronquée de C16Y.
Csaky Karl G.
Kleinman Hynda
Ponce Lourdes
Department Of Health And Human Services Government Of The United States Of America As Represented By Sec
Smart & Biggar
LandOfFree
Therapeutic administration of the scrambled anti-angiogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic administration of the scrambled anti-angiogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic administration of the scrambled anti-angiogenic... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1496901